+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Continuous Glucose Monitoring Systems Market (2021-2026) by Component, End User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 178 Pages
  • June 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5410409
The Global Continuous Glucose Monitoring Systems Market is estimated to be USD 4.34 Bn in 2021 and is expected to reach USD 6.71 Bn by 2026, growing at a CAGR of 9.1%.



Market Dynamics

Factors driving the continuous glucose monitoring market are the worldwide rise in the prevalence of diabetes, increasing demand for less minimally invasive or non-invasive diagnosis, and point-of-care devices. Additionally, increasing R&D investments by government and privately held companies are driving market’s growth. However, the high cost of the products, frequent product replacement and ineffective reimbursement, the strict regulations by the government, and safety issues are anticipated to hinder the market growth.
Moreover, the growing awareness of smart devices and digital platforms, increasing awareness and management of diabetes, creates opportunities for the continuous glucose monitoring market.

Market Segmentation

The Global Continuous Glucose Monitoring Systems Market is segmented further based on Component, End User, and Geography.

By Component, the market is classified into Transmitters & Receivers, Sensors, and Insulin Pumps. Amongst all, the sensors segment is estimated to hold the highest market share during the forecast period.

By End User, the market is classified as Hospitals, Home Care, Diagnostics Clinics, and others. Amongst all, the Hospitals segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. Abbott received FDA approval for its FreeStyle Libre 3 system - diabetes device as an iCGM (integrated continuous glucose monitor). - 15th June 2020
2. Tandem Diabetes Care Announces Commercial Launch of the t:slim X2 Insulin Pump with Control-IQ Technology in the United States. The system is integrated with Dexcom G6 continuous glucose monitoring. - 15th January 2020

Company Profiles

Some of the companies covered in this report are Abbott Laboratories, AgaMatrix Inc, Bayer AG, DexCom, Inc, Echo Therapeutics, Inc., etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Continuous Glucose Monitoring Systems Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Continuous Glucose Monitoring Systems Market

What is the estimated value of the Global Continuous Glucose Monitoring Systems Market?

The Global Continuous Glucose Monitoring Systems Market was estimated to be valued at $4340 Million in 2021.

What is the growth rate of the Global Continuous Glucose Monitoring Systems Market?

The growth rate of the Global Continuous Glucose Monitoring Systems Market is 9.1%, with an estimated value of $6710 Million by 2026.

What is the forecasted size of the Global Continuous Glucose Monitoring Systems Market?

The Global Continuous Glucose Monitoring Systems Market is estimated to be worth $6710 Million by 2026.

Who are the key companies in the Global Continuous Glucose Monitoring Systems Market?

Key companies in the Global Continuous Glucose Monitoring Systems Market include Abbott Laboratories, AgaMatrix Inc., Bayer AG, DexCom, Inc., Echo Therapeutics, Inc., F. Hoffmann, La Roche Ltd., GlySens Incorporated and Johnson & Johnson Services Inc..

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Increase in Prevalence Of Diabetes
4.1.2 Technological Developments And Growing Awareness
4.2 Restraints
4.2.1 Low Awareness
4.2.2 Successive Effects Of Any Error In Accuracy On Measurement
4.3 Opportunities
4.3.1 A Large Number Of Undiagnosed Patient Population
4.3.2 Increasing Acceptance Rate Of In-Home Healthcare
4.4 Challenges
4.4.1 Reimbursement And Stringent Regulatory Concerns
4.5 Trends
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Continuous Glucose Monitoring Systems Market, By Component
6.1 Introduction
6.2 Transmitters & Receivers
6.3 Sensors
6.4 Insulin Pumps
7 Global Continuous Glucose Monitoring Systems Market, By End-Use
7.1 Introduction
7.2 Hospitals
7.3 Homecare
7.4 Diagnostics/ Clinics
7.5 Others
8 Global Continuous Glucose Monitoring Systems Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 South America
8.3.1 Brazil
8.3.2 Argentina
8.3.3 Chile
8.3.4 Colombia
8.4 Europe
8.4.1 UK
8.4.2 France
8.4.3 Germany
8.4.4 Italy
8.4.5 Spain
8.4.6 Netherlands
8.4.7 Sweden
8.4.8 Russia
8.4.9 Rest of Europe
8.5 Asia-Pacific
8.5.1 China
8.5.2 Japan
8.5.3 India
8.5.4 Indonesia
8.5.5 Malaysia
8.5.6 South Korea
8.5.7 Australia
8.5.8 Sri Lanka
8.5.9 Thailand
8.5.10 Rest of APAC
8.6 Middle-East and Africa
8.6.1 Qatar
8.6.2 Saudi Arabia
8.6.3 South Africa
8.6.4 United Arab Emirates
9 Competitive Landscape
9.1 Competitive Quadrant
9.2 Market Share Analysis
9.3 Strategic Initiatives
9.3.1 M&A and Investments
9.3.2 Partnerships and Collaborations
9.3.3 Product Developments and Improvements
10 Company Profiles
10.1 Abbott Laboratories
10.2 AgaMatrix Inc.
10.3 Bayer AG
10.4 DexCom, Inc.
10.5 Echo Therapeutics, Inc.
10.6 F. Hoffmann-La Roche Ltd.
10.7 GlySens Incorporated
10.8 Insulet Corporation
10.9 Johnson & Johnson Services Inc.
10.10 LifeScan Inc.
10.11 Medtronic PLC
10.12 Medtrum Technologies Inc.
10.13 Menarini Diagnostics S.r.l.
10.14 Nemaura Medical Inc.
10.15 Novo Nordisk A/S
10.16 NXP Semiconductors N.V.
10.17 Senseonics Holdings, Inc.
10.18 STMicroelectronics
10.19 Tandem Diabetes Care, Inc.
10.20 Texas Instruments Inc
10.21 ViCentra B.V.
10.22 WaveForm Technologies, Inc
10.23 Ypsomed Group
11 Appendix
11.1 Questionnaire

Companies Mentioned

  • Abbott Laboratories
  • AgaMatrix Inc.
  • Bayer AG
  • DexCom, Inc.
  • Echo Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlySens Incorporated
  • Insulet Corporation
  • Johnson & Johnson Services Inc.
  • LifeScan Inc.
  • Medtronic PLC
  • Medtrum Technologies Inc.
  • Menarini Diagnostics S.r.l.
  • Nemaura Medical Inc.
  • Novo Nordisk A/S
  • NXP Semiconductors N.V.
  • Senseonics Holdings, Inc.
  • STMicroelectronics
  • Tandem Diabetes Care, Inc.
  • Texas Instruments Inc
  • ViCentra B.V.
  • WaveForm Technologies, Inc
  • Ypsomed Group